Further genomic studies have identified a loss of function mutation in NF-κB inhibitors (TRAF2, TRAF3, and BIRC3) associated with primary ibrutinib resistance in MCL cell lines. This evidence concerns the gene BIRC3 and mantle cell lymphoma.